What is InpharmD?
InpharmD is a provider of updated, scientifically supported data and evidence-based recommendations. The company specializes in delivering concise and detailed information, offering rapid responses to clinical questions related to pharmacy. InpharmD excels at linking conclusions from various studies and provides excellent explanations about drug uses, side effects, and research. While the company provides detailed answers, there is an opportunity for more focused conclusions. It serves as a valuable and accessible resource for drug information and comparisons, supported by evidence.
How much funding has InpharmD raised?
InpharmD has raised a total of $6M across 1 funding round:
Other Financing Round
$6M
Other Financing Round (2023): $6.1M with participation from Y Combinator, 645 Ventures, Atlanta Ventures, and Qlarant
Key Investors in InpharmD
Y Combinator
Y Combinator is a well-known accelerator program that provides seed funding and mentorship to early-stage startups, helping them to grow and secure further investment.
645 Ventures
645 Ventures is a venture capital firm focused on seed and Series A SaaS companies, actively supporting founders in customer acquisition, talent recruitment, and fundraising.
Atlanta Ventures
Atlanta Ventures is dedicated to empowering entrepreneurs in the Southeastern US by providing community, content, and capital, with a focus on systematically growing subscription-based businesses.
What's next for InpharmD?
The substantial enterprise-level funding InpharmD has garnered suggests a pivotal growth phase, likely aimed at scaling operations, expanding its data repository, and enhancing its recommendation engine. This strategic investment will likely fuel further development of its evidence-based platform, enabling InpharmD to solidify its position as a leading provider of critical pharmaceutical data. Future initiatives may include broadening its market reach and integrating advanced analytics to offer even more targeted and actionable insights to its clientele.
See full InpharmD company page
